NCT06957002View on ClinicalTrials.gov

Bosentan in the Treatment of Giant Cell Arteritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Giant Cell Arteritis (GCA)
Interventions
DRUG

Bosentan

Bosentan : 62.5 mg twice a day for 4 weeks and 125 mg twice a day during 9 weeks (treatment length 3 months)

DRUG

Glucocorticoids

prespecified GC tapering schedule

Trial Locations (1)

75005

Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER